Self-Administered Parenteral Trends and Forecast
The future of the global self-administered parenteral market looks promising with opportunities in the cardiovascular disease, diabetes, osteoporosis, pain management, and hormone replacement markets. The global self-administered parenteral market is expected to grow with a CAGR of 5.5% from 2024 to 2030. The major drivers for this market are growing significance of specialty drugs & biologics, increasing acceptance of options for home-based therapy, and growing use of smart injection tools.
• Lucintel forecasts that, within the product type category, pre-filled syringe segment is expected to witness the highest growth over the forecast period due to its growing demand for practical and safe medicine delivery systems.
• Within the application category, pain management is expected to witness the highest growth over the forecast period.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period.
A more than 150-page report is developed to help in your business decisions.
Emerging Trends in the Self-Administered Parenteral Market
The self-administered parenteral market has catered to the latest trends, which include various developments that have changed the direction of the industry. These emerging trends are driven by advancements in technology and new patient requirements.
• Advancement in Device Design: New inventions of devices, particularly auto-injectors that are lightweight, more ergonomic, and easier to use, are improving the lives of patients. Better designs lead to easier and more convenient self-administration, resulting in better adherence rates.
• Integration with Digital Health: Most devices used for self-administration have started incorporating digital health technologies. Components such as connectivity and data tracking provide enhanced monitoring and management of patients, leading to improved outcomes.
• Needle-Free Technologies: The development of systems that allow patients to receive injections without needles is on the rise. These technologies offer a gentler and more patient-friendly experience, which will boost compliance and reduce needle phobia.
• Personalized Medicine: There is a growing trend toward personalized medicine, where self-administered parenteral devices are customized for each patient. This includes tailoring the medication and injection schedule according to the patientÄX%$%Xs needs.
• Focus on Patient Education: There is a growing need for patient education and support to prevent non-adherence to requirements and ensure the safe use of self-administered devices. Every patient receives adequate training beforehand to promote correct usage.
All these trends are reshaping the self-administered parenteral market by improving device usability, integrating digital health, and advancing patient-centered strategies. Technological innovations and the development of personalized medicine are the main contributors to market growth and better patient outcomes.
Recent Developments in the Self-Administered Parenteral Market
The self-administered parenteral market has shown significant progress in technology, design, and ease of use. These developments are defining the future of the market.
• Enhanced Auto-Injectors: Ergonomically designed auto-injectors with user-friendly interfaces are being developed. These advancements make devices easier for patients to handle and use, improving patient compliance and satisfaction.
• Wearable Injectors: The emergence of wearable injectors that can infuse drugs over an extended period is expanding the scope of treatment for chronic diseases. These devices allow for continuous drug intake, leading to better patient compliance.
• Needle-Free Injections: The development of needle-free injection systems is reducing the pain associated with injections. These systems administer medication without the use of needles, making them gentler on patients.
• Digital Integration: More self-administered parenteral devices are being augmented with digital health technology. These devices help track data and monitor patients, providing enhanced patient management.
• Cost-Effective Solutions: There is a growing trend to develop low-cost self-administered parenteral products for emerging markets. Reasonably priced solutions are being created to meet the needs of a broader patient base.
In conclusion, these trends are reshaping the self-injectable drug market by enhancing the utility and convenience of delivery devices. Technological developments and cost-cutting initiatives are helping make self-administered therapies more accessible and user-friendly.
Strategic Growth Opportunities for Self-Administered Parenteral Market
The self-administered parenteral market presents several growth opportunities across various applications. These opportunities are driven by technological advancements and changing patient experiences.
• Management of Chronic Illness: The use of self-injectable devices extends to managing chronic diseases. There are opportunities to develop sophisticated devices that can constantly deliver medication to patients, aiding in the management of conditions like diabetes and arthritis.
• Cancer Therapies: The growth of personalized cancer therapies opens up opportunities for self-managed injection treatments. Advanced drug delivery systems will support person-based treatment approaches that offer greater benefits to patients.
• Increased Penetration in Developing Nations: Self-administered injectable therapies are gaining acceptance in developing countries such as Brazil and India, which show high potential for these therapies. The market strategy focuses on developing affordable and accessible solutions for these regions.
• Self-Administered Devices and Telehealth: The combination of self-administered parenteral devices and telehealth solutions presents new opportunities for remote patient monitoring and management. This combination may lead to enhanced treatment compliance and better health outcomes.
• Technological Evolution: The continued advancement of device technology, including the development of needle-free systems and device connectivity, opens avenues for innovation. These innovations can improve patient comfort and expand the range of treatment options.
The degree of technological change in the self-administered parenteral market highlights significant growth opportunities. Companies can leverage these opportunities for market expansion by targeting chronic conditions, focusing on new regions, and advancing technological developments.
Self-Administered Parenteral Market Driver and Challenges
The self-administered parenteral market is affected by a number of drivers and challenges including technological advancements, policies, and economics. It is important to have an understanding of the concerns due to their impact on success in the market.
The factors responsible for driving the self-administered parenteral market include:
• Technological Innovations: Increase in the device such as auto-injectors, needle free systems is propelling the market growth. These innovations enhance compliance with the treatment regimens by improving usability and comfort to patients.
• Rising Chronic Diseases: Self-administered parenteral therapies are increasingly in demand due to rising cases of chronic diseases such as diabetes and rheumatoid arthritis. There is a strong market for devices which provide convenient and efficient management alternatives.
• Patient Convenience: There is growing adoption of self-administered parenteral devices due to increased focus on patient convenience and autonomy. There is also a growing trend of use of devices to allow patients to manage their treatment from their homes.
• Healthcare Cost Reduction: Patients undertaking self-administered therapy can lower the frequent hospital visits by patients and also the need of professional administration which is an expensive expenditure. This cost-reduction approach is a currently one of the leading market growth factors.
• Regulatory Support: Self-administered devices is gaining acceptability and necessary regulatory support which is expanding the market. The development of clear and straightforward guidelines and standards also makes it possible to innovate and introduce new devices into the market.
Challenges in the self-administered parenteral market are:
• High Development Costs: The high cost of developing modern self-administered parenteral devices can be burdensome, especially for lower-tier companies. This affects the cost and competitiveness of the market.
• Regulatory Hurdles: Navigating the extensive regulatory landscape and obtaining approval for new devices is challenging. Meeting the requirements of various jurisdictions requires significant resources and expertise.
• Market Competition: The self-administered parenteral market is highly competitive, with many manufacturers and products. It is easy for companies to lose market share due to the availability of competing products.
Technological progress and the increasing demand for comfortable treatment options are driving the self-administration of parenteral medications market. However, development costs and regulatory barriers remain significant challenges. Addressing these issues is crucial for maintaining market momentum and success.
List of Self-Administered Parenteral Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies self-administered parenteral companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the self-administered parenteral companies profiled in this report include-
• Becton, Dickinson and Company
• scPharmaceuticals
• Harro Höfliger
• Owen Mumford
• Haselmeier
• Stevanato Group
• Ypsomed AG
• Solteam Group
• AstraZeneca
• Enable Injections
Self-Administered Parenteral by Segment
The study includes a forecast for the global self-administered parenteral by product type, usage, distribution channel, application, and region.
Self-Administered Parenteral Market by Product Type [Analysis by Value from 2018 to 2030]:
• Pre-Filled Syringes
• Auto injectors
• Pen Injectors
• Others
Self-Administered Parenteral Market by Usage [Analysis by Value from 2018 to 2030]:
• Disposable
• Reusable
Self-Administered Parenteral Market by Distribution Channel [Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Online Pharmacies
• Home Healthcare Providers
• Specialty Clinics
• Others
Self-Administered Parenteral Market by Application [Analysis by Value from 2018 to 2030]:
• Cardiovascular Diseases
• Diabetes
• Osteoporosis
• Pain Management
• Hormone Replacement
• Others
Self-Administered Parenteral Market by Region [Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Self-Administered Parenteral Market
Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. The following highlights recent developments by major self-administered parenteral producers in key regions: the USA, China, India, Japan, and Germany.
• United States: The U.S. market has seen a growing trend toward more sophisticated self-injection devices, including auto-injectors and wearable injectors, which improve patient comfort and compliance. Similar advancements are also being seen in needle-free injectors.
• China: The Chinese market is gradually advancing toward self-administered parenteral products, largely due to increased investment in healthcare and the development of chronic disease management programs. Domestic companies are creating affordable alternatives to meet the growing local demand.
• Germany: Germany is a leader in the market for self-injectable parenteral therapies, incorporating e-health technologies. Recent developments include connected devices that can share data and remotely monitor patients.
• India: In India, the focus is on enhancing the availability and affordability of self-administered parenteral therapies. Companies are launching low-cost solutions and expanding their distribution to reach a broader patient population.
• Japan: In Japan, there are developments in self-administered parenteral devices aimed at improving ease of use and comfort. These include smart injectors that assist users and provide guidance, aligning with Japan’s emphasis on precision and quality.
Features of the Global Self-Administered Parenteral Market
Market Size Estimates: Self-administered parenteral market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecasts (2024 to 2030) by various segments and regions.
Segmentation Analysis: Self-administered parenteral market size by various segments, such as by product type, usage, distribution channel, application, and region in terms of value ($B).
Regional Analysis: Self-administered parenteral market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different product types, usages, distribution channels, applications, and regions for the self-administered parenteral market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the self-administered parenteral market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What is the growth forecast for self-administered parenteral market?
Answer: The global self-administered parenteral market is expected to grow with a CAGR of 5.5% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the self-administered parenteral market?
Answer: The major drivers for this market are growing significance of specialty drugs & biologics, increasing acceptance of options for home-based therapy, and growing use of smart injection tools.
Q3. What are the major segments for self-administered parenteral market?
Answer: The future of the self-administered parenteral market looks promising with opportunities in the cardiovascular disease, diabetes, osteoporosis, pain management, and hormone replacement markets.
Q4. Who are the key self-administered parenteral market companies?
Answer: Some of the key self-administered parenteral companies are as follows:
• Becton, Dickinson and Company
• scPharmaceuticals
• Harro Höfliger
• Owen Mumford
• Haselmeier
• Stevanato Group
• Ypsomed AG
• Solteam Group
• AstraZeneca
• Enable Injections
Q5. Which self-administered parenteral market segment will be the largest in future?
Answer: Lucintel forecasts that pre-filled syringe segment is expected to witness the highest growth over the forecast period due to its growing demand for practical and safe medicine delivery systems.
Q6. In self-administered parenteral market, which region is expected to be the largest in next 5 years?
Answer: APAC is expected to witness the highest growth over the forecast period.
Q.7 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the self-administered parenteral market by product type (pre-filled syringes, auto injectors, pen injectors, and others), usage (disposable and reusable), distribution channel (hospital pharmacies, online pharmacies, home healthcare providers, specialty clinics, and others), application (cardiovascular diseases, diabetes, osteoporosis, pain management, hormone replacement, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Self-Administered Parenteral Market, Self-Administered Parenteral Market Size, Self-Administered Parenteral Market Growth, Self-Administered Parenteral Market Analysis, Self-Administered Parenteral Market Report, Self-Administered Parenteral Market Share, Self-Administered Parenteral Market Trends, Self-Administered Parenteral Market Forecast, Self-Administered Parenteral Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.